| 1.68 -0.04 (-2.33%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.04 | 1-year : | 2.38 |
| Resists | First : | 1.75 | Second : | 2.04 |
| Pivot price | 1.49 |
|||
| Supports | First : | 1.39 | Second : | 1.17 |
| MAs | MA(5) : | 1.64 |
MA(20) : | 1.49 |
| MA(100) : | 1.55 |
MA(250) : | 1.82  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 94.2 |
D(3) : | 91 |
| RSI | RSI(14): 57.7 |
|||
| 52-week | High : | 3.44 | Low : | 1.17 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BYSI ] has closed below upper band by 13.1%. Bollinger Bands are 36.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.73 - 1.74 | 1.74 - 1.75 |
| Low: | 1.66 - 1.67 | 1.67 - 1.68 |
| Close: | 1.66 - 1.68 | 1.68 - 1.7 |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Mon, 18 May 2026
BeyondSpring Inc. to Present Study 303 on Plinabulin Combination Therapy for NSCLC at ASCO 2026 - Quiver Quantitative
Mon, 18 May 2026
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting - GlobeNewswire
Mon, 18 May 2026
Phase 2 plinabulin combo in resistant NSCLC to appear at 2026 ASCO - Stock Titan
Sun, 17 May 2026
Number of shareholders of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Wed, 13 May 2026
BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI) - Yahoo Finance
Wed, 13 May 2026
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 14.8 (%) |
| Held by Institutions | 14.5 (%) |
| Shares Short | 2,190 (K) |
| Shares Short P.Month | 2,200 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | 13 (M) |
| PE Ratio | -8.4 |
| PEG Ratio | 0 |
| Price to Book value | -2.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|